3004517
print

Paraneoplastic Reflexive Panel, CSF

PNSPAN CSF
Example Reports
Negative
Positive

Icon

Additional Technical Information

Ordering Recommendation

Aids in the diagnosis of paraneoplastic neurologic syndromes. 

This test only evaluates for the presence of high-risk paraneoplastic antibodies, independent of neurologic phenotype. Targeted phenotype-specific panels are preferred for the evaluation of autoimmune neurologic disease. Refer to the ARUP Autoimmune Neurology Panel Components tables for phenotype-specific test options.

Testing in both serum and CSF is recommended to maximize diagnostic yield; refer to Paraneoplastic Reflexive Panel (3002929) for serum testing.

New York DOH Approval Status

This test is not New York state approved.

Specimen Required

Patient Preparation
Collect

CSF.

Specimen Preparation

Transfer 2 mL CSF to an ARUP Standard Transport Tube. (Min: 1 mL).

Storage/Transport Temperature

Refrigerated

Unacceptable Conditions

Contaminated, heat-inactivated, hemolyzed, or lipemic specimens

Remarks
Stability

Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month

Methodology

Semi-Quantitative Indirect Fluorescent Antibody/Qualitative Immunoblot

Performed

Wed

Reported

1-9 days

Reference Interval

Test Number
 Components
 Reference Interval
  Paraneoplastic Abs (PCCA/ANNA) IgG, CSF None Detected
  CV2.1 Ab IgG CBA-IFA Screen, CSF Less than 1:1
  SOX1 Antibody, IgG by Immunoblot, CSF Negative
  Amphiphysin Antibody, CSF Negative

Interpretive Data

Refer to report 

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)

Note

Purkinje Cell (PCCA) antibody and Neuronal Nuclear (ANNA) antibody IgG are screened by IFA. If the IFA screen is indeterminate, then a Neuronal Nuclear Antibodies (Hu, Ri, Yo, Tr/DNER) IgG by Immunoblot will be added. If the IFA screen is positive at 1:1 or greater, then a PCCA/ANNA antibodies titer and Neuronal Nuclear Antibodies (Hu, Ri, Yo, Tr/DNER) IgG by Immunoblot will be added. Additional charges apply.
If CV2.1 Antibody IgG Screen by IFA is positive, then CV2.1 Antibody IgG Titer by IFA will be added. Additional charges apply.

Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
08/21/2023
X
02/22/2022
X
N/A

CPT Codes

86255 x2; 84182 x2; if reflexed add 86256 and/or 84182 x4; if reflexed add 86256

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
2010842 Paraneoplastic Abs (PCCA/ANNA) IgG, CSF 14247-1
3002259 CV2.1 Ab IgG CBA-IFA Screen, CSF 53707-6
3002904 SOX1 Antibody, IgG by Immunoblot, CSF 94383-7
3004511 Amphiphysin Antibody, CSF 57750-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

Paraneoplastic Reflexive Panel, CSF